ProFactor Pharma’s executive directors, Jaymin Amin, CEO, and Richard Cruse, CFO, visited PT Bio Farma (Persero) (BFI) who recently licensed PFP’s patented process to make low-cost Factor VIII treatment for Haemophilia A.
Jaymin met with BFI’s CEO, Mr. Honesti Basyir, at the company’s head office in Bandung, Indonesia where they exchanged gifts.
Richard and Jaymin received an extremely warm welcome and had a full day of meetings with the BFI team comprising R&D, process development, scale-up and clinical trials personnel. They were joined in the afternoon by PFP’s experts via Zoom.
They were also given a tour of the impressive BFI R&D facility which is currently undergoing an expansion into a purpose-built GLP/GMP facility.
The technology transfer of the PFP process into the BFI R&D laboratories is scheduled for April 2023 with technical and logistical support from PFP and Ingenza.
All in all, this was an extremely useful and productive meeting in which the whole BFI team expressed their commitment and enthusiasm for the project and an eagerness to make progress.